OSOnesource Specialty Pharma544292Pharmaceuticals, CDMO

OneSource Specialty Pharma CEO Neeraj Sharma discussed Q2 results and growth drivers including semaglutide supplies to Dr Reddy's for Canada, biologics and a new cartridge line

By ScoutQuest · Thu 29 Oct 2026, 12:12 PM IST · 1 min read

Revenue growth YoY

37 percent

FY28 revenue guidance

400 million dollars

FY28 margin guidance

28 percent

Heard on business television between 12:15:39 - 12:18:39 IST.

• Revenue grew 37% YoY with margin expansion and manifold profit jump in the September quarter.
• API supplies for semaglutide have begun to Dr Reddy's for Canada relaunch in November and other markets; all four current approvals are OneSource customers.
• Company guided for $400 million revenue by FY28 with ~28% margins, contributed by semaglutide, biologics, injectables and soft gel businesses.
• Highest ever RFP activity seen, onboarded a new US biotech customer; biologics is a high-margin business but commercialization will happen beyond FY28, in 2029-30.
• New cartridge line with more than twice existing capacity is now operational, helping meet robust demand from Canada and other new markets; companies are diversifying supply chains away from single-country dependence, benefiting India and OneSource.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev